Will Sanofi’s Dengvaxia Woes Spiral Beyond The Philippines?
Sanofi appears to be under mounting pressure in the Philippines over deaths allegedly linked to its dengue vaccine and after declining to refund costs of the doses already used in the Southeast Asian nation’s vaccination plan. Whether or not the goings on could have a domino effect could be crucial for the product’s future.
You may also be interested in...
As Takeda pays down debt associated with the acquisition of Shire and advances R&D programs toward global filings, the company is selling its growth plan to investors – but are they buying?
Long-anticipated findings for Japanese firm’s dengue vaccine show efficacy rates above its only rival, including in those not previously exposed to the virus, but results for different strains were mixed and experts are awaiting additional data due in the next few weeks.
CBER’s novel biologic approvals in 2018 were few, long, and with a low level of innovation. But the center’s work to build regulatory framework for emerging technologies is setting the stage for a different story in 2019.